Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
ISELIN, N.J., Dec. 23, 2022 -- Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in... | December 23, 2022